As a "Patients Helping Patients" organization, MSWorld is supporting the ALS Icebucket Challenge. All donations received by MSWorld from this challenge will go directly to support ALSA.org.
The model was created by directly injecting human cerebrospinal fluid (CSF) derived from patients with progressive MS into the CSF “pockets†of mice brain. This resulted in typical lesions of MS forming in the animal brains with immune cells, loss of myelin and nerve damage. This unique model may now be employed to discover the underlying events that lead to these pathological changes as thus better understand disease activity and progression.
To read this full article, click here. TISCH MS Research Center of New York
Results from two phase I human safety trials of an exploratory treatment aimed at repairing myelin damaged by multiple sclerosis have now been published. One to two treatments with Biogen Idec’s BIIB033 (anti-LINGO monoclonal antibody) were given by injection under the skin or into the vein of healthy volunteers and people with relapsing-remitting or secondary-progressive MS. No serious adverse safety events were reported, and although these studies were not designed to evaluate effectiveness, the results were considered positive and have led to a phase II trial, now underway in relapsing MS. The results were published on August 27, 2014 in the online journal Neurology® Neuroimmunology & Neuroinflammation.
Nintendo may have provided your family with endless hours of entertainment, and now it seems it may also have some therapeutic value. A new study shows the Nintendo Wii Balance Board system helps to improve brain connections in people with multiple sclerosis (MS), thus helping them to improve their overall balance and reduce their risk of accidental falls. The study, published in Radiology, used magnetic resonance imaging (MRI) scans on the brains of 27 patients to arrive at this conclusion.
To read this full article, click here. Medical Daily August 26, 2014 Summary: Investigators at several centers nationwide are recruiting 172 people with relapsing-remitting MS to compare the effectiveness of the current recommended amount of vitamin D supplementation versus high dose vitamin D supplementation at reducing MS disease activity, when added to standard therapy with glatiramer acetate (Copaxone®, Teva Pharmaceutical Industries). The principal investigator is Ellen Mowry, MD, MCR (Johns Hopkins University, Baltimore) and the study is funded by a research grant from the National MS Society, with partial support from the Society's Greater Delaware Valley Chapter.
To read this full article, click here. National MS Society - August 26, 2014
Chat Schedule
The following chat schedule is hosted by MSWorld Volunteers
SPECIAL NOTE: If you have a pop-up blocker you may not be able to view links listed in this newsletter. You can set your blocker to temporarily allow pop-ups.
Information shared on all aspects of MSWorld.org is not intended to be used towards the diagnosis or treatment of any medical condition. For specific information and advice, consult your personal physician. - MSWorld Management
MSWorld provides the message board and chat services for the National MS Society. We are proud to have been a collaborative partner with the NMSS since 2001.
